Tivicay
GSK unveils strong showing for twin-drug HIV treatment
February 14, 2017Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, HIV, Tivicay
GlaxoSmithKline has announced strong Phase 3 findings for its own Tivicay (dolutegravir) as part of a twin-drug regimen with J&J’s …
ViiV Healthcare launches Phase III trial for combo HIV treatment
August 16, 2016Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III
The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …
GSK mulls $27 billion ViiV sell-off
October 23, 2014Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV
After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …
HIV pill Tivicay gains FDA approval
August 14, 2013Sales and Marketing FDA, GSK, Tivicay, ViiV
ViiV and partner GlaxoSmithKline’s new HIV drug Tivicay has been shown the FDA’s green light for distribution in the US. …
